CL2025001329A1 - Composición farmacéutica de liberación controlada - Google Patents

Composición farmacéutica de liberación controlada

Info

Publication number
CL2025001329A1
CL2025001329A1 CL2025001329A CL2025001329A CL2025001329A1 CL 2025001329 A1 CL2025001329 A1 CL 2025001329A1 CL 2025001329 A CL2025001329 A CL 2025001329A CL 2025001329 A CL2025001329 A CL 2025001329A CL 2025001329 A1 CL2025001329 A1 CL 2025001329A1
Authority
CL
Chile
Prior art keywords
controlled
pharmaceutical composition
release pharmaceutical
nausea
vomiting
Prior art date
Application number
CL2025001329A
Other languages
English (en)
Inventor
Young Park Min
Won Kim Gyoung
Eun Cho Sang
Young Kim Gwan
HA Songyi
HWANG On
Kwon Seonju
Kim Dongyoon
Choi Jongwon
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of CL2025001329A1 publication Critical patent/CL2025001329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación que puede inhibir la liberación inicial de un inhibidor de PRS específico, y tiene el efecto de prevenir los efectos secundarios de náuseas o vómitos que se producen cuando se absorbe una cantidad excesivamente grande del principio activo en la etapa inicial.
CL2025001329A 2022-11-11 2025-05-06 Composición farmacéutica de liberación controlada CL2025001329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020220150695A KR20240069303A (ko) 2022-11-11 2022-11-11 방출 제어형 약학적 조성물

Publications (1)

Publication Number Publication Date
CL2025001329A1 true CL2025001329A1 (es) 2025-08-18

Family

ID=91033213

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001329A CL2025001329A1 (es) 2022-11-11 2025-05-06 Composición farmacéutica de liberación controlada

Country Status (13)

Country Link
EP (1) EP4616850A1 (es)
JP (1) JP2026505928A (es)
KR (1) KR20240069303A (es)
CN (1) CN120076795A (es)
AR (1) AR131032A1 (es)
AU (1) AU2023378146A1 (es)
CL (1) CL2025001329A1 (es)
CO (1) CO2025005587A2 (es)
JO (1) JOP20250106A1 (es)
MX (1) MX2025005360A (es)
PE (1) PE20251703A1 (es)
TW (1) TWI866596B (es)
WO (1) WO2024101937A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
AU2020283238B2 (en) * 2019-05-31 2022-07-07 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
KR20220154617A (ko) * 2021-05-13 2022-11-22 주식회사 대웅제약 섬유화증의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
KR20240069303A (ko) 2024-05-20
TW202425985A (zh) 2024-07-01
JOP20250106A1 (ar) 2025-05-08
WO2024101937A1 (ko) 2024-05-16
PE20251703A1 (es) 2025-07-02
EP4616850A1 (en) 2025-09-17
CO2025005587A2 (es) 2025-05-19
AR131032A1 (es) 2025-02-12
JP2026505928A (ja) 2026-02-20
AU2023378146A1 (en) 2025-04-24
TWI866596B (zh) 2024-12-11
MX2025005360A (es) 2025-06-02
CN120076795A (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
CL2022002695A1 (es) Inhibidores de rip1k
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
CL2024000271A1 (es) Formas de dosificación gastrorretentivas de 5-hidroxitriptófano
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
MX2024002885A (es) Inhibidor de la proteasa 3clpro.
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
MX2024010155A (es) Formulacion combinada de cedazuridina
CL2025001329A1 (es) Composición farmacéutica de liberación controlada
PE20231048A1 (es) Composicion insecticida sinergica
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
CL2025001923A1 (es) Composición farmacéutica que comprende enavogliflozina y metformina
MX2025008705A (es) Sistema para el suministro oral de un ingrediente activo
CL2024002912A1 (es) Una composición agroquímica
ECSP23088732A (es) Moduladores de trex1
JOP20220260A1 (ar) تركيبة صيدلانية تشتمل على مركب مشتق من البنزيميدازول
PE20242056A1 (es) Composiciones secuestradoras de etileno con propiedades antimicrobianas
MX2025006988A (es) Composicion para la prevencion o tratamiento de los efectos secundarios de los inhibidores de colinesterasa
AR133910A1 (es) Composición fitosanitaria y método fitosanitario
MX2023003087A (es) Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.
AR126259A1 (es) Combinación de cinamaldehído y eugenol con actividad antimicótica
UY40059A (es) Una composición que comprende un principio activo y un ramnolípido
CL2024002218A1 (es) Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico
CL2025003172A1 (es) Composición farmacéutica estable que comprende dexrabeprazol.